Ipsen SA IPN.PA:
* IPSEN AND SKYHAWK THERAPEUTICS ANNOUNCE THE SIGNATURE OF A RESEARCH COLLABORATION AGREEMENT AIMING AT RNA TARGETING IN RARE NEUROLOGICAL DISEASES
* IPSEN ENTERS INTO AN OPTION AGREEMENT FOR THE EXCLUSIVE GLOBAL RIGHTS OF THE CANDIDATES SELECTED UNDER THIS COLLABORATION
* ONCE THE DEVELOPMENT CANDIDATE IS VALIDATED, IPSEN WILL BE RESPONSIBLE FOR ITS CONTINUED DEVELOPMENT AND COMMERCIALIZATION BUILDING ON ITS EXPERTISE IN NEUROSCIENCES AND MOVEMENT DISORDERS
* THE PROMISING TECHNOLOGY PLATFORM CREATED BY SKYHAWK ALLOWS TO ADDRESS, VIA SMALL MOLECULES, RNA TARGETS THAT ARE OTHERWISE NOT Amenable to DRUG DEVELOPMENT
Original text on Workspace For more details, click IPN.PA
(Gdańsk editorial office)